ArticleChembiochem : a European journal of chemical biology2026
A Robust Bioprocess for the Global Incorporation of Noncanonical Amino Acids in Auxotrophic Hosts Produces Labeled Proteins at the Gram Scale.
Article in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Robust Bioprocess for the Global Incorporation of Noncanonical Amino Acids in Auxotrophic Hosts Produces Labeled Proteins at the Gram Scale.Chembiochem : a European journal of chemical biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study presents a robust bioprocess for the global incorporation of noncanonical amino acids (ncAAs) into proteins, enabling gram-scale production in auxotrophic Escherichia coli strains. The two-phase approach adapts from shake flask to bioreactor cultures and relies on cost-effective synthetic minimal media with glucose as the sole carbon source and yeast extract as an amino acid supply. It supports both external ncAA supplementation and in situ biosynthesis. A versatile E. coli BL21(DE3) auxotroph platform ensures broad ncAA and protein compatibility. Model proteins, such as a thermophilic lipase (TTL) and an oxidoreductase are labeled with biosynthesized norleucine (Nle), synthetic fluoroprolines, and fluorophenylalanine. Under optimal conditions, we achieved titers of up to 2 g L
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.